In part 1 of this Exclusive Interview, Dr. Julia Greenstein talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about research plans at the JDRF.
Dr. Julia Greenstein, PhD, is the Vice President of Discovery Research at the JDRF.
Transcript of this video segment:
Steve Freed: This is Steve Freed. We’re here at the American Diabetes Association 77th Scientific Studies and we’re here to present you some exciting interviews with some of the top endos from all over the world and it’s Dr. Greenstein and maybe you can give us a little history and talk about who you are and what you do.
Julia Greenstein: Sure, I’ve been at JDRF for about ten years. Prior to that I spent a lot of time in the biotech industry and as well in academic medicine, and I’m in charge of setting the tragedy across our cure and prevent portfolio, helping our teams make critical decisions about what JDRF will fund and how we’ll build our programs.
Steve Freed: So, let me ask you a couple of questions. You know with some of the new research, theories, and pathways you’ve heard about this week over here at ADA, how do they fit into the JDRF’s strategic plans for research? Anything new JDRF that might pursue based on what you have seen and learned this week?
Julia Greenstein: So, there’s a ton of exciting science going on in both type 1 and type 2 diabetes and we’re really excited about the more complete understanding we’re starting to get about the pathways involved in beta cell biology that can help a person with type 1 diabetes. It turns out that beta cell stress as well as the immune system are contributing to the pathways of initiating and continuing the destruction of the beta cells in type 1 and that gives us an opportunity to both look for pathways and therapies that could eliminate the beta cell stress. It also gives us the opportunity to understand better the autoimmune response and find ways to inhibit that.